How We Work

Anacor Pharmaceuticals

Back

Print

CHALLENGE

There are a limited number of drug candidates for treating infectious diseases caused by bacteria, fungi and parasites. We are seeking more chemically diverse leads.

PROGRAM STRATEGY

The foundation is committed to researching new drugs for a number of infectious diseases that disproportionately impact individuals in developing countries. Therapeutics provide effective health interventions. The potential for introduction of boron into an existing carbon structure can create a new generation of drug leads for treating infectious diseases.

PARTNER

Anacor Pharmaceuticals, Inc.
Biopharmaceutical company developing therapeutics derived from boron chemistry platform. Lead products in onychomycosis, atopic dermatitis and psoriasis.

Foundation focus: To fund the discovery of three preclinical drug candidates for filarial diseases and TB and to expand the company’s boron chemistry library

INVESTMENT

Common stock
Date: April 2013
Co-Investors: None
Associated funding: Contract to fund discovery of preclinical drug candidates for filarial disease and TB and to expand the company’s boron chemistry library

Visit Our Blog

Connect